At the intersection of molecular biology and materials engineering, researchers from Nagoya University and Fujifilm have found a way to make the body's own protein-making machinery work harder and longer — by rethinking the very shape of the message it receives. Their Cap-cirRNA technology, paired with a purpose-built lipid carrier, delivers genetic instructions into cells with tenfold greater efficiency while quieting the inflammatory responses that have long constrained mRNA medicine. It is an early but meaningful step toward a future where a single injection might sustain a therapeutic effe
Nagoya University, Fujifilm Achieve 10x Efficiency Boost in mRNA Delivery Technology
Cells keep making the protein for longer from a single dose
Mark
Why does it matter that the RNA is circular instead of linear? Isn't it still the same genetic information?
Mimi
The shape changes everything about how the body treats it. Linear mRNA is like a piece of string—enzymes can grab either end and start chewing it up. Circular RNA has no ends, so it survives much longer in the bloodstream and inside cells. But that durability comes with a cost: cells are less efficient at reading it and turning it into protein.
Mark
So Cap-cirRNA solves that by doing what, exactly?
Mimi
It adds a chemical cap—a kind of flag—to the circular structure that tells the cell's protein-making machinery, "This is important, read me." It's borrowing the signal that linear mRNA naturally carries. Now you get both: the longevity of circular and the readability of linear.
Mark
And the lipid nanoparticle—why does FL0445 work better than what they were using before?
Mimi
The branched structure creates space inside the particle. Circular RNA is rigid, almost like a wheel. You need room to fit it in without crushing it. The older lipids were too tightly packed. FL0445 is flexible enough to cradle it properly.
Mark
The mouse study showed better glucose control. Is that because the GLP-1 lasted longer, or because more of it got into cells?
Mimi
Both, really. The ten-fold efficiency means more mRNA reaches the cells in the first place. And because it's circular, the cells keep making GLP-1 for longer. So you get a higher dose and a longer duration from a smaller injection.
Mark
What's the biggest hurdle before this reaches patients?
Mimi
Safety and scale. They've shown it works in mice. Now they need to prove it doesn't cause unexpected problems in larger animals, then in humans. And they need to figure out how to manufacture it reliably at the scale required for actual patients. That's where most promising lab discoveries fail.
O Pulso
- Current mRNA therapies degrade rapidly inside the body, forcing patients into cycles of repeated dosing that strain both health and quality of life.
- Circular RNA resists breakdown far better than linear mRNA, but cells have historically struggled to read it efficiently — a paradox that has blocked its clinical use.
- The Nagoya-Fujifilm team cracked this paradox by engineering Cap-cirRNA, a hybrid molecule that borrows durability from circular RNA and translation efficiency from linear mRNA, then pairing it with a flexible lipid nanoparticle designed to carry its rigid structure.
- In obese mice treated for diabetes, the new system produced longer-lasting hormone expression, improved blood sugar control, and measurably reduced inflammation compared to conventional approaches.
- The technology now sits at the threshold between animal proof-of-concept and the long road of human clinical trials — promising in principle, but not yet ready for the clinic.
At the intersection of molecular biology and materials engineering, researchers from Nagoya University and Fujifilm have found a way to make the body's own protein-making machinery work harder and longer — by rethinking the very shape of the message it receives. Their Cap-cirRNA technology, paired with a purpose-built lipid carrier, delivers genetic instructions into cells with tenfold greater efficiency while quieting the inflammatory responses that have long constrained mRNA medicine. It is an early but meaningful step toward a future where a single injection might sustain a therapeutic effect for months, sparing patients the burden of repeated treatment.
A research collaboration between Nagoya University and Fujifilm has produced a delivery system for messenger RNA that outperforms existing methods by more than tenfold — while generating fewer of the inflammatory side effects that have limited mRNA medicine since its earliest applications. The advance builds on a deceptively elegant insight: circular RNA, which has no exposed ends to degrade, lasts far longer inside the body than the linear form used in most therapies, including COVID-19 vaccines. The catch has always been that cells translate circular RNA into proteins less efficiently. The team resolved this tension by engineering Cap-cirRNA, which grafts a chemical cap structure onto circular RNA to restore its translational power without sacrificing its durability.
To carry this engineered molecule into cells, Fujifilm contributed an ionizable lipid called FL0445, whose branched, flexible architecture is specifically suited to enclosing the rigid geometry of circular RNA. Together, the two components form a lipid nanoparticle system that, in cell culture tests, delivered its payload more than ten times more effectively than conventional carriers.
The researchers then moved to living animals, encoding GLP-1 — a hormone central to diabetes treatment — within Cap-cirRNA and administering it to obese mice. The results were notable: sustained hormone production, better glucose regulation, and a suppressed inflammatory response, all compared to mice receiving standard linear mRNA. Professor Hiroshi Abe highlighted that smaller doses achieving greater effect, with reduced side effects, could fundamentally change how mRNA drugs are administered for chronic conditions.
The implications reach beyond diabetes. Cancer vaccines, hereditary disease therapies, and gene-editing applications all stand to benefit from a delivery system this efficient and this tolerable. Still, the findings — published in Cell Biomaterials — represent a proof of principle, not a clinical solution. Extensive preclinical work and human trials lie ahead before this technology could reach patients. What it has done is move the horizon meaningfully closer: a future where a single mRNA injection sustains its effects for months, rather than days, is now a more credible destination.
A team of researchers at Nagoya University and Fujifilm has engineered a new way to deliver messenger RNA into cells—one that works more than ten times better than existing methods while triggering fewer of the inflammatory side effects that have plagued earlier approaches. The breakthrough centers on a deceptively simple idea: if you want RNA to stick around longer and do its job more effectively, make it circular instead of linear.
For decades, mRNA has been understood as a molecular courier, ferrying genetic instructions from the cell nucleus outward so the body can manufacture proteins on demand. The COVID-19 vaccines proved the concept could work at scale. But getting mRNA into cells in the first place has always been the hard part. Researchers wrap it in lipid nanoparticles—tiny fat-based containers—to smuggle it past the cell membrane. The trouble is that conventional, linear mRNA degrades quickly once inside the body, forcing patients to return for repeated doses. Circular mRNA, which has no beginning or end, resists that degradation far better. Yet it has its own problem: cells struggle to translate it into actual proteins as efficiently as they do with the linear version.
The Nagoya-Fujifilm team solved this by creating what they call Cap-cirRNA, essentially adding a chemical cap structure to circular RNA that gives it the translation efficiency of linear mRNA while preserving the durability of the circular form. They then paired this engineered RNA with an ionizable lipid called FL0445, developed by Fujifilm, whose branched architecture creates internal flexibility—crucial for transporting the rigid structure of circular RNA. When they tested this combination in cultured cells, the transport efficiency exceeded conventional lipid nanoparticles by more than tenfold.
To demonstrate real-world potential, the researchers encapsulated Cap-cirRNA encoding GLP-1, a hormone used in diabetes treatment, and administered it to obese mice. The results were striking. The mice receiving the circular RNA version showed longer-lasting GLP-1 production, better blood glucose control, and notably suppressed inflammatory responses compared to those given conventional linear mRNA. This matters because inflammation is one of the most significant side effects limiting current mRNA therapeutics. The durability also suggests that patients might eventually need far fewer injections—a major quality-of-life improvement for conditions requiring ongoing treatment.
Professor Hiroshi Abe of Nagoya University emphasized that the approach enables mRNA therapeutics to achieve their effects with smaller doses while reducing side effects, a dual benefit that could reshape how these drugs are administered. The potential applications extend well beyond diabetes management. Cancer vaccines, gene-editing therapies, and treatments for hereditary diseases caused by missing or defective proteins all become more feasible with a delivery system this efficient and this gentle on the body.
Yet the path forward remains long. The findings, published in the journal Cell Biomaterials, represent a crucial proof of principle—that durable circular RNA can be delivered safely and efficiently into living cells. But animal studies are only the beginning. Researchers must now conduct extensive preclinical testing and eventually human clinical trials to confirm that what works in mice translates to patients. The technology is not ready for the clinic, but it has moved significantly closer to the day when a single injection of mRNA therapy might sustain its effects for months or longer, transforming how we treat diseases that currently demand constant medical intervention.
Citações Notáveis
This enables mRNA therapeutics that sustain their effects with smaller amounts of active ingredient. It also contributes to reducing side effects.— Professor Hiroshi Abe, Nagoya University
Quer a matéria completa?
Leia o original em finance.biggo.com ↗
Health & Medicine